Floatz logo

Adebelizumab

Advanced or Metastatic Non-small Cell Lung Cancer

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Advanced or Metastatic Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Shr-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2B
Tas-114
Taiho Oncology, Inc.
Phase 2B
Shr-A2102 For
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2CC
iap0971
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2CC
Bbp-398
LianBio LLC
Phase 1D

Same molecule, other indications

Adebelizumab is also rated in:

small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →